Table 1. Patients, tumor and treatment characteristics.
| Characteristic | Value |
|---|---|
| Age at PCA diagnosis, years | |
| Median (range) | 62 (47–75) |
| PSA at PCA diagnosis, ng/mL | |
| Median (range) | 9.8 (0.54–159) |
| PSA at SBRT, ng/mL | |
| Median (range) | 1.9 (0.16–59.8) |
| Gleason score, N (%) | |
| ≤6 | 3 (6) |
| 7 | 28 (56) |
| ≥8 | 18 (36) |
| unknown | 1 (2) |
| Primary tumor size (T), N (%) | |
| c/pT1-T2b | 16 (32) |
| c/pT2c-T3 | 32 (64) |
| Tx | 2 (4) |
| Regional lymph node involvement at PCA diagnosis, N (%) | |
| c/pN0 | 36 (72) |
| c/pN1 | 11 (22) |
| Nx | 3 (6) |
| PCA treatment, N (%) | |
| RP | 15 (30) |
| RT | 4 (8) |
| RP and RT | 31 (62) |
| ADT at the time of SBRT, N (%) | |
| no | 35 (70) |
| yes | 15 (30) |
| Time to metastases from diagnosis of PCA (months) | |
| Median (range) | 37 (1–199) |
| Number of metastases treated at first SBRT, N (%) | |
| 1 | 35 (70) |
| 2 | 9 (18) |
| 3 | 3 (6) |
| 4 | 2 (4) |
| 5 | 1 (2) |
| Primary site of metastases, N (%) | |
| Lymph node | 24 (48) |
| Pelvic | 15 (62.5) |
| Extra-pelvic | 8 (33.3) |
| Both | 1 (4.2) |
| Bone | 23 (46) |
| Bone and lymph node | 2 (4) |
| Lung | 1 (2) |
| Maximal SUV of PSMA-PET/CT | |
| Median (range) | 6 (2.6–42) |
| Fractionation schedules, N (%) | |
| SFRS | 60 (80) |
| 3 fractions | 13 (17.3) |
| other | 2 (2.7) |
| Median dose (Gy) for SFRS (range) | 20 (16–25) |
| Median dose (Gy) for fSBRT(range) | 24 (19.2–28.8) |
Abbreviations: ADT = androgen deprivation therapy; fSBRT = fractionated stereotactic body radiotherapy; PCA = prostate cancer; PSA = prostate-specific antigen; PSMA-PET/CT = prostate-specific membrane antigen positron emission tomography/computed tomography; RP = radical prostatectomy; RT = radiotherapy; SBRT = stereotactic body radiotherapy; SFRS = single fraction radiosurgery; SUV = standardized uptake value.